Alemtuzumab and rheumatoid arthritis - an immunisation study

Trial Profile

Alemtuzumab and rheumatoid arthritis - an immunisation study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; DT-poliovirus vaccine; Influenza virus vaccine; Pneumococcal vaccine
  • Indications Diphtheria; Influenza virus infections; Pneumococcal infections; Poliomyelitis; Rheumatoid arthritis; Tetanus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Mar 2015 Accrual to date is 55% according to United Kingdom Clinical Research Network.
    • 03 Mar 2015 Status changed from recruiting to active, no longer recruiting, according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top